id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2333-0008,FDA,FDA-2020-E-2333,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-04-05T04:00:00Z,2024,4,2024-04-05T04:00:00Z,,2024-04-05T18:36:28Z,,0,0,09000064864bd15a
FDA-2020-E-2333-0007,FDA,FDA-2020-E-2333,Letter from FDA CDER to U.S.  Patent and Trademark Office,Other,Letter(s),2024-01-25T05:00:00Z,2024,1,2024-01-25T05:00:00Z,,2024-01-25T14:46:33Z,,0,0,09000064863c1f74
FDA-2020-E-2333-0006,FDA,FDA-2020-E-2333,Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction,Notice,Correction,2023-11-17T05:00:00Z,2023,11,2023-11-17T05:00:00Z,,2023-11-17T21:08:13Z,2023-25489,0,0,090000648628cc11
FDA-2020-E-2333-0005,FDA,FDA-2020-E-2333,Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Determinations,2022-07-08T04:00:00Z,2022,7,2022-07-08T04:00:00Z,2022-09-07T03:59:59Z,2023-11-17T21:08:02Z,2022-14546,0,0,09000064851b6d71
FDA-2020-E-2333-0004,FDA,FDA-2020-E-2333,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2022-06-14T04:00:00Z,2022,6,2022-06-14T04:00:00Z,,2022-06-14T16:48:50Z,,0,0,0900006485162e1f
FDA-2020-E-2333-0003,FDA,FDA-2020-E-2333,Patent Term Extension letter from FDA CDER to Honorable Drew Hirshfeld,Other,Extension of Time,2021-03-01T05:00:00Z,2021,3,2021-03-01T05:00:00Z,,2021-03-01T17:16:32Z,,0,0,0900006484a57d3e
FDA-2020-E-2333-0001,FDA,FDA-2020-E-2333,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-12-23T05:00:00Z,2020,12,2020-12-23T05:00:00Z,,2020-12-23T13:01:31Z,,0,0,09000064849c0a4b
FDA-2020-E-2333-0002,FDA,FDA-2020-E-2333,"Patent Term Extension Application for ROZLYTREK® Patent No 8,299,057",Other,Application,2020-12-23T05:00:00Z,2020,12,2020-12-23T05:00:00Z,,2020-12-23T13:02:47Z,,0,0,09000064849c0a4c